lidocaine has been researched along with Cytokine Release Syndrome in 2 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasan, D | 1 |
| Shono, A | 1 |
| van Kalken, CK | 1 |
| van der Spek, PJ | 1 |
| Krenning, EP | 1 |
| Kotani, T | 1 |
| Ali, ZA | 1 |
| El-Mallakh, RS | 1 |
1 review available for lidocaine and Cytokine Release Syndrome
| Article | Year |
|---|---|
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
Topics: Adenosine Triphosphate; Anti-Inflammatory Agents; COVID-19; Critical Care; Cytokine Release Syndrome | 2022 |
1 other study available for lidocaine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Nebulized Lidocaine in COVID-19, An Hypothesis.
Topics: Administration, Inhalation; Anesthetics, Local; Anti-Inflammatory Agents; COVID-19; COVID-19 Drug Tr | 2020 |